AGIOS PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
AGIO$31.38+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (In thousands, except share and per share data) December 31: | 2025 | 2024 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $89,130 | $76,247 |
| Marketable securities | 765,295 | 817,463 |
| Accounts receivable, net | 10,577 | 4,109 |
| Inventory | 32,920 | 27,616 |
| Prepaid expenses and other current assets | 44,130 | 40,165 |
| Total current assets | 942,052 | 965,600 |
| Marketable securities | 310,013 | 638,321 |
| Operating lease assets | 30,454 | 42,879 |
| Property and equipment, net | 10,775 | 11,675 |
| Other non-current assets | 3,931 | 4,724 |
| Total assets | $1,297,225 | $1,663,199 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $18,355 | $16,643 |
| Accrued expenses | 45,459 | 46,861 |
| Income taxes payable | — | 871 |
| Operating lease liabilities | 18,392 | 16,781 |
| Total current liabilities | 82,206 | 81,156 |
| Operating lease liabilities, net of current portion | 21,815 | 40,207 |
| Other non-current liabilities | 90 | 880 |
| Total liabilities | 104,111 | 122,243 |
| Commitments and contingent liabilities (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized; 74,665,003 shares issued and 58,448,592 outstanding at December 31, 2025 and 73,372,696 shares issued and 57,156,285 outstanding at December 31, 2024 | 75 | 73 |
| Additional paid-in capital | 2,555,037 | 2,493,811 |
| Accumulated other comprehensive income (loss) | 2,193 | (1,518) |
| Accumulated deficit | (561,705) | (148,924) |
| Treasury stock, at cost (16,216,411 shares at December 31, 2025 and December 31, 2024) | (802,486) | (802,486) |
| Total stockholders’ equity | 1,193,114 | 1,540,956 |
| Total liabilities and stockholders’ equity | $1,297,225 | $1,663,199 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.